Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)
← catalyst calendarNCT01088360 · readout in 1,046 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →. With National Data Bank for Rheumatic Diseases (NDB).
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
20,000estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2005-03-31 | actual | When the study began enrolling |
| Primary completion | 2029-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2010-03-17 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2019-01-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Rheumatoid Arthritis
Primary outcome
what the primary-completion date above is the date OFKey safety outcomes (targeted infections, malignancies, mortality)
measured Every 6 months throughout the study
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed